Table 1.
Study Cohort
| CoV2+ | HCs | |
|---|---|---|
| Number of participantsa | 15 | 17 |
| Age (years) | 47 (28–71) | 42 (24–57) |
| Sex | 27% male, 73% female |
47% male, 53% female |
| Number of symptomsb,c | 5 (1–7) | NAd |
| Symptom duration (days) | 13 (2–31) | NA |
| Time from symptom onset to Visit 1 (days) | 35.5 (19–44) | NA |
| Time from symptom onset to Visit 2 (days) | 86 (73–110) | NA |
| Time from SARS-CoV-2 positive PCR test to Visit 1 (days) | 28 (20–35) | NA |
| Time from SARS-CoV-2 positive PCR test to Visit 2 (days) | 77.5 (64–97) | NA |
| Time from Visit 1 to Visit 2 (days) | 46 (39–69) | 47 (40–61) |
Previously SARS-CoV-2-infected (CoV2+) and HC volunteers were consented and enrolled for this study. Values are reported as the median with the range in parentheses.
a
Blood drawn from 14 CoV2+ and 13 HCs at Visit 1 and Visit 2. One CoV2+ and 2 HCs were only drawn with Visit 1. Two HCs were only drawn with Visit 2.
b
All CoV2+ individuals reported symptoms. Nine HCs reported symptoms, and 2 HC had negative SARS-CoV-2 PCR results.
c
The symptoms surveyed were fever, chills, cough, runny nose, fatigue, muscle ache, and difficulty breathing.
d
NA = Not applicable.